NECTAR LIFESCIENCES
|
NECTAR LIFESCIENCES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -5.07 | 0.22 | -1.08 | 1.12 | -3.27 |
| CEPS(Rs) | -2.29 | 2.93 | 1.56 | 3.66 | -0.58 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 42.63 | 47.68 | 47.47 | 48.51 | 47.36 |
| Tax Rate(%) | 29.62 | 72.66 | 42.99 | 26.51 | 13.57 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | -1.55 | 7.87 | 3.03 | 8.23 | 5.75 |
| EBIT Margin(%) | -4.43 | 5.60 | 2.69 | 5.86 | 1.55 |
| Pre Tax Margin(%) | -8.46 | 0.95 | -2.43 | 1.77 | -4.81 |
| PAT Margin (%) | -5.96 | 0.26 | -1.38 | 1.30 | -4.15 |
| Cash Profit Margin (%) | -2.69 | 3.41 | 2.00 | 4.26 | -0.74 |
| Performance Ratios | |||||
| ROA(%) | -5.44 | 0.23 | -1.06 | 1.05 | -2.93 |
| ROE(%) | -11.23 | 0.47 | -2.25 | 2.33 | -6.67 |
| ROCE(%) | -5.21 | 6.12 | 2.49 | 5.77 | 1.41 |
| Asset Turnover(x) | 0.91 | 0.88 | 0.77 | 0.81 | 0.70 |
| Sales/Fixed Asset(x) | 1.17 | 1.22 | 1.12 | 1.23 | 1.15 |
| Working Capital/Sales(x) | 8.83 | 6.19 | 5.13 | 5.49 | 34.29 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.85 | 0.82 | 0.89 | 0.81 | 0.87 |
| Receivable days | 69.30 | 62.43 | 75.92 | 77.89 | 79.75 |
| Inventory Days | 133.82 | 130.94 | 139.23 | 118.26 | 161.98 |
| Payable days | 114.43 | 112.09 | 109.47 | 107.25 | 137.11 |
| Valuation Parameters | |||||
| PER(x) | - | 135.18 | - | 21.53 | - |
| PCE(x) | -10.05 | 10.28 | 10.18 | 6.58 | -32.06 |
| Price/Book(x) | 0.54 | 0.63 | 0.33 | 0.50 | 0.39 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 0.65 | 0.77 | 0.72 | 0.83 | 0.84 |
| EV/Core EBITDA(x) | -48.80 | 7.66 | 10.29 | 8.13 | 11.48 |
| EV/EBIT(x) | -12.76 | 11.97 | 23.26 | 12.24 | 47.49 |
| EV/CE(x) | 0.70 | 0.76 | 0.60 | 0.71 | 0.66 |
| M Cap / Sales | 0.31 | 0.40 | 0.23 | 0.32 | 0.27 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -0.84 | 10.53 | -8.70 | 8.13 | -34.78 |
| Core EBITDA Growth(%) | -113.10 | 58.97 | -37.56 | 50.54 | -49.64 |
| EBIT Growth(%) | -178.30 | 129.83 | -58.42 | 314.00 | -83.30 |
| PAT Growth(%) | -2,375.90 | 120.66 | -196.55 | 134.19 | -330.47 |
| EPS Growth(%) | -2,375.91 | 120.66 | -196.55 | 134.19 | -326.69 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.61 | 0.59 | 0.71 | 0.79 | 0.85 |
| Current Ratio(x) | 1.21 | 1.32 | 1.38 | 1.35 | 1.04 |
| Quick Ratio(x) | 0.54 | 0.59 | 0.63 | 0.69 | 0.55 |
| Interest Cover(x) | -1.10 | 1.20 | 0.53 | 1.43 | 0.24 |
| Total Debt/Mcap(x) | 1.13 | 0.94 | 2.12 | 1.59 | 2.17 |
Compare Financial Ratios of peers of NECTAR LIFESCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NECTAR LIFESCIENCES | ₹359.1 Cr | 14.6% | 3% | -57.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹411,822.0 Cr | -0.2% | 3.6% | -7.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹172,811.0 Cr | -2.4% | 9.1% | 13.4% | Stock Analytics | |
| CIPLA | ₹127,688.0 Cr | -5.7% | 4% | 6.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹121,840.0 Cr | -0.3% | 1.3% | 8.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹104,544.0 Cr | 0.1% | 1.2% | -2.8% | Stock Analytics | |
NECTAR LIFESCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NECTAR LIFESCIENCES | 14.6% |
3% |
-57.8% |
| SENSEX | 0.7% |
4.7% |
6.1% |
You may also like the below Video Courses
